Dr. Daniel Latham, Novartis - PFS18 Qepler Conferences & Summits

Dr. Daniel Latham

Head of Device Development Operation,
Global Drug Development

Novartis,
Basel, Switzerland
Novartis is a global healthcare company

Daniel Latham is Head of Device Development Operations in Global Drug Development, Novartis, where he leads an organization responsible for developing delivery systems for combination products for new biologic entities, biosimilars and small molecules.

During the past 10 years at Novartis he has overseen significant device and primary packaging developments and launches and has significantly supported the growth of device development and combination products within the organization.

Prior to Novartis he working in a variety of roles in consumer healthcare focusing on the development of OTC medicines, transdermal patches and medical devices.

He has a PhD in controlled drug delivery from Queen Mary's, University of London and Bachelor and Master's degrees in Engineering from the University of Sheffield.

Related Sessions:

Pre-Filled Syringes
Summit 2018

  • 31-May-2018
  • Berlin, DE
  • Pharma
Day 1: Thursday 31, May 2018
BLOCK: DEVICES MEET NEXT GENERATION FORMULATIONS.
CASE STUDY: Developing delivery systems comprising pre-filled syringes and injection devices.
  • Combination products and delivery systems – reducing development risk.
  • Importance of understanding the design space of a delivery system.
  • Considerations for setting up platforms for delivery systems.
View Details